At AutoCruitment, we believe that diversity and inclusion are essential to advancing medical research and improving health outcomes for all.
Our direct-to-patient targeting strategies have successfully recruited a diverse patient population, with 48% of our database comprised of non-white patients.
We are dedicated to diversity in patient recruitment so the patients in the clinical trial are reflective of the intended use population. Our commitment to diversity and inclusion is at the heart of everything we do, and we strive to create a welcoming and supportive environment for participants from all backgrounds.
Comprehensive Research: Diverse participation in clinical trials helps ensure that research findings are applicable to a wide range of populations. This leads to more accurate and reliable data, ultimately improving the effectiveness of treatments for everyone.
Health Equity: By actively seeking to include underrepresented groups in our studies, we address health disparities and contribute to more equitable healthcare solutions.
Innovation: Diversity drives innovation. By bringing together people with different perspectives, we foster creativity and novel approaches to solving complex health challenges.
We have been successful at enrolling a diverse population for all indications. Our database is composed of 48% non-white participants (based on all who have reported race), ensuring a rich diversity of perspectives and experiences.
We can support trial sponsors with site selection and provide recommendations on best-fit sites based on diversity requirements.
We customize each of our campaigns to be tailored to the audience we are targeting. This includes creative development and strategic targeting to ensure we are in front of the right audience, and tailored messaging to touch on the areas they care about most.
We assist our clients in crafting the appropriate language for their DAP, ensuring clarity and compliance with FDA guidelines.
AutoCruitment’s patient recruitment platform supports Sponsors, CRO Partners and Research Sites by decreasing time, risk and cost to bring new therapies to market.
